214 related articles for article (PubMed ID: 33549147)
1. Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide.
Zheng Y; Mao YF; Zhao HJ; Chen L; Wang LN; Zhang YX; Hu J; Li JM; Li XY; Zhu HM
Exp Hematol Oncol; 2021 Feb; 10(1):10. PubMed ID: 33549147
[TBL] [Abstract][Full Text] [Related]
2. Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients.
Guo M; Lv J; Chen X; Wu M; Zhao Q; Hai X
Front Oncol; 2022; 12():887026. PubMed ID: 35646703
[TBL] [Abstract][Full Text] [Related]
3. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
[No Abstract] [Full Text] [Related]
4. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As
Liu WS; Wang XY; Lu J; Zhang YM; Ye XM; Li JM; Zhao QL; Wu ZQ; Zhou J; Hai X
Arch Toxicol; 2020 Apr; 94(4):1203-1213. PubMed ID: 32112223
[TBL] [Abstract][Full Text] [Related]
5. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
[TBL] [Abstract][Full Text] [Related]
6. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.
Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J
Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140
[TBL] [Abstract][Full Text] [Related]
7. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
[TBL] [Abstract][Full Text] [Related]
8. Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
Lv J; Wu M; Pang C; Duan R; Zhang H; Tian S; Yang H; Hai X
Biomed Pharmacother; 2023 Jul; 163():114858. PubMed ID: 37172335
[TBL] [Abstract][Full Text] [Related]
9. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang Z; Zhou J; Lu X; Gong Z; Le XC
Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
Gao C; Hu S; Guo M; Hai X; Zhou J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
[TBL] [Abstract][Full Text] [Related]
11. Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment.
Chen B; Cao F; Lu X; Shen S; Zhou J; Le XC
Talanta; 2018 Jul; 184():446-451. PubMed ID: 29674067
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
[No Abstract] [Full Text] [Related]
13. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Ghiuzeli CM; Stýblo M; Saunders J; Calabro A; Budman D; Allen S; Devoe C; Dhingra R
Leuk Lymphoma; 2022 Mar; 63(3):653-663. PubMed ID: 34689693
[TBL] [Abstract][Full Text] [Related]
14. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As
Guo M; Li J; Fan S; Liu W; Wang B; Gao C; Zhou J; Hai X
J Pharm Biomed Anal; 2019 Jul; 171():212-217. PubMed ID: 31009876
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
Guo M; Zhao Q; Fan S; Wu Z; Lin L; Chen H; Gao Y; Hai X
Br J Clin Pharmacol; 2021 Oct; 87(10):4020-4026. PubMed ID: 33638869
[TBL] [Abstract][Full Text] [Related]
16. Speciation of arsenic in biological samples.
Mandal BK; Ogra Y; Anzai K; Suzuki KT
Toxicol Appl Pharmacol; 2004 Aug; 198(3):307-18. PubMed ID: 15276410
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide.
Wang X; Qian Z; Li H; Chen H; Lin L; Guo M; Hai X
J Pharm Biomed Anal; 2021 Sep; 203():114201. PubMed ID: 34130006
[TBL] [Abstract][Full Text] [Related]
18. Influence of genetic polymorphisms on arsenic methylation efficiency during pregnancy: Evidence from a Spanish birth cohort.
Soler-Blasco R; Harari F; Riutort-Mayol G; Murcia M; Lozano M; Irizar A; Marina LS; Zubero MB; Fernández-Jimenez N; Braeuer S; Ballester F; Llop S
Sci Total Environ; 2023 Nov; 900():165740. PubMed ID: 37495132
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
20. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Chen B; Cao F; Yuan C; Lu X; Shen S; Zhou J; Le XC
Anal Bioanal Chem; 2013 Feb; 405(6):1903-11. PubMed ID: 23318765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
